GlassScriptPhysician profile
Christopher Michael Freese
NPI 1689084261
$2,066.39
in general payments reported to CMS, 2019-2025
24 companies · $14.33 in 2025
The $14.33 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.70 · 2022: $1,702 · 2023: $336 · 2025: $14.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $350.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $1,332.70 | 2022 | |
| Janssen Biotech, INC. | $73.38 | 2019-2023 | Imbruvica, Darzalex, Carvykti |
| Merck Sharp & Dohme LLC | $69.54 | 2022-2023 | Keytruda |
| Ethicon INC. | $65.58 | 2022 | |
| Novartis Pharmaceuticals Corporation | $58.30 | 2022 | |
| Amgen INC. | $52.24 | 2022-2023 | Kyprolis, Blincyto |
| Pharmacyclics LLC, An Abbvie Company | $43.41 | 2022 | |
| Adaptive Biotechnologies Corporation | $38.92 | 2022-2023 | Clonoseq |
| Puma Biotechnology, INC. | $37.30 | 2023 | Nerlynx |
| Bayer Healthcare Pharmaceuticals INC. | $35.66 | 2023 | |
| Visionrt, INC. | $34.25 | 2023 | |
| Tersera Therapeutics LLC | $33.78 | 2022-2023 | Zoladex |
| Sun Pharmaceutical Industries INC. | $22.46 | 2023 | Yonsa, Odomzo |
| Celgene Corporation | $18.84 | 2022 | |
| Genentech USA, INC. | $16.74 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $16.25 | 2022 | |
| Lilly USA, LLC | $16.09 | 2023 | Retevmo, Jaypirca, Verzenio |
| Stemline Therapeutics INC. | $16.00 | 2023 | Orserdu |
| Genzyme Corporation | $15.52 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.45 | 2022 | |
| Sumitomo Pharma America, INC. | $14.33 | 2025 | Orgovyx |
| Siemens Medical Solutions USA, INC. | $13.61 | 2023 | Somatom Go.Top |
| Astrazeneca Pharmaceuticals LP | $13.16 | 2023 | |
| Palette Life Sciences, INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Freese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.